Loading transcript...
Click for full transcript
Chapters & Sections (257)
▼
00:01
Podcast Host Greeting and Guest Introduction
00:34
Governor Perry’s Role in Kentucky Opioid Initiative
01:06
Personal Relationship Development with Governor Perry
01:39
Early Vacation and Unexpected Meeting at Carata Island
02:09
Misidentified Security Detail Encounter
02:42
Tour of the Special Warfare Center
03:14
Discussion of Operation Redwing and Military Connections
04:16
Discovery of Marcus Latrell’s Identity
05:20
Introduction to Jake Elie and Congressional Connection
05:52
Marcus Latrell’s Residency and Long-Term Support
06:25
Veterans Mental Health Advocacy Journey
06:56
Challenges in Veterans Healthcare System
07:28
Securing Medical Care for Marcus Latrell
07:58
Engagement with Secretary of the Navy and Advocacy Outcomes
09:02
Mental Health Support for Veterans
09:32
Foundation Home Donation Initiative
10:04
Personal Journey into Plant Medicine
10:34
Educational Mission on Psychoactive Plants
11:06
Political Advocacy for Medical Use of THC
11:38
Shift from Opposition to Support in 2013
12:09
Clarifying Medical vs. Recreational Use
13:13
Role of Trump Administration in Plant Medicine
13:46
Personal Commitment to Public Health
14:18
Evidence of Plant Medicine on Addiction
14:51
Health Routine and AG1 Promotion
15:22
AG1 Product Details and Offer
16:24
ExpressVPN Privacy Features
17:25
ExpressVPN Promotion and Free Months Offer
18:28
Hunter S. Thompson’s Role in Fake News
18:59
Dick Cavett Show and the Rumor Spread
19:29
Gonzo Journalism’s Impact on Public Perception
20:00
Schedule I Classification and Political Motives
20:31
Veterans as a Key Population for Plant Medicine
21:02
Compassionate Care and Mental Health Challenges
21:32
Early Life and Military Aspirations
22:04
Drug Testing Culture in the 1970s
22:36
International Use of Ibigan for Clinical Trials
23:09
Frustration with Government Stance on Ibigan
24:16
Political Support for Plant Medicine Initiatives
24:47
Clinical Trial Planning and Scheduling Goals
25:21
Veteran Treatment Organization Formation
25:51
Personal Story of Marcus Capone and Amber
26:22
Mission Clinic in Mexico for Ibigan Treatment
26:53
Veteran Support Group and Travel to Ibigan Clinic
27:23
Stanford Clinical Trial Outcomes
27:54
Psychological Testing Before and After Treatment
28:25
MRI Comparisons with Healthy Brain Database
28:56
Veteran Outcomes and Suicide Risk Reduction
29:26
White Matter Regeneration Observed in Veterans
29:58
Case Example of Parkinson’s Disease Treatment Abroad
30:29
Deep Brain Stimulation Procedure Details
31:02
Post‑Surgery Functional Limitations
31:35
Four‑Week Abigan Course and Recovery
32:04
Patient’s Return to Normal Functioning
32:37
Comparison of Abigan Dosing Strategies Internationally
33:09
Potential for Widespread Clinical Trials
33:40
Publication in Nature Medicine and Recognition by Research Foundation
34:11
Early Exposure to Abigan Through a Veteran Friend
34:43
Veteran Community’s Experience with Mexico Treatment Centers
35:13
Personal Skepticism and Subsequent Confirmation
35:45
Connection to Energy Department Supercomputing Resources
36:17
First Encounter with Abigan Through Military Networks
36:51
Academic Interest Sparked by Veteran Friend’s Story
37:21
Stanford Study Overview and Participant Profile
37:52
PTSD Reduction Statistics
38:26
Long-Term Symptom Elimination
38:56
Advocacy for Federal Clinical Trials
39:26
Political Consultant Interaction
39:58
Personal Conviction and Reputation Trade-Off
40:30
Veteran Success Stories
41:00
Public Figures Endorsing Treatment
41:32
Veteran Care Critique and Opioid Crisis
42:32
Burn Center Observations
43:05
Government Opioid Distribution Criticism
43:36
Historical Warfare Duration Comparison
44:07
Evolution of Military Trauma Treatment
44:37
Modern Combat Stress Factors
45:09
Continuous Threat Environment Impact
45:39
Policy Opportunity for Clinical Trials
46:12
Texas Legislative Initiative Overview
46:45
Unique Pathway for Ibogaine in Addiction Treatment
47:18
Early 1960s Ibogaine Use by Howard Lotsof
48:21
Neurochemical Basis of Opioid Dependence
49:26
Ibigan’s Restoration of Dopamine and Serotonin Levels
50:58
Comparative Success Rates of Traditional Treatments
52:19
Cardiac Risk: QT Interval and Torsades de Pointes
53:10
Mitigation with Magnesium Co‑Administration
54:14
Clinical Standards and Professional Oversight
55:10
Early Life in a Coal‑Mining Community
56:04
Family History of Substance Abuse and Mental Illness
57:18
Personal Reflections on Faith and Purpose
58:26
Sanctuary and Spiritual Support in Early Years
58:58
Idealized American History and Family Expectations
59:30
Law School Debt and Disillusionment with Legal Ideals
1:00:02
Accidental Entry into Workers Compensation Law
1:01:06
Mentorship and Loss of Mary Kay Williams
1:01:36
Managing Walmart Client Case Load
1:02:08
Representing Workers in the Opioid Crisis
1:02:41
Deposition Techniques and Pain Documentation
1:04:15
Emotional and Spiritual Dimensions of Chronic Pain
1:05:19
Medication-Induced Disability and Systemic Critique
1:06:20
State-Level Evaluation of Social Security Disability
1:07:24
Acceptance of Kentucky Social Security Disability Role
1:07:55
Team Assembly and Policy Metrics Development
1:08:26
Retrospective Study Highlights (1980-2015)
1:08:59
Medicaid Prescription Opioid Trends (2001-2015)
1:09:30
Opioid and Psychotropic Medication Increase (2001-2015)
1:10:02
Federal Liaison Home Agency Visit Overview
1:10:34
Claims Reduction and Budget Impact Discussion
1:11:05
Child Support Enforcement System Structure
1:12:08
County Attorney Property Ownership Issues
1:12:41
Termination and Transition to Medicaid Fraud Office
1:13:12
Medicaid Fraud Investigations and Indictments
1:14:46
Opioid Commission Opportunity and Kentucky Context
1:16:53
Settlement Allocation and Long‑Term Impact
1:17:25
Identifying a Breakthrough Therapeutic Opportunity
1:17:57
Discovery of the Silen Cyon Mushroom
1:18:28
Engagement with Juliana Christina and Psychedelic Inquiry
1:19:01
Juliana Mulligan’s Story of Addiction and Recovery
1:20:03
Experiences with Suboxone and IAG Research
1:20:35
Introduction to Adriana Curzer and the Plant Medicine Law Firm
1:21:08
Networking with Researchers, Activists, and Philanthropists in New York
1:23:14
Confidentiality and Strategic Planning for Kentucky
1:23:45
Presentation to Attorney General Cameron and Funding Proposal
1:24:48
Approval of $42 Million Public‑Private Partnership for IAG Development
1:25:18
Announcement of FDA Approval Initiative
1:25:50
First Public Hearing on Scientific Basis
1:26:20
Second Public Hearing with Patient Testimonials
1:26:51
Third Public Hearing on FDA Approval Viability
1:27:23
Cardiac Risk Testimony by FDA Scientists
1:27:55
Mitigation of Cardiac Risk and Clinical Trial Approval
1:28:26
Funding Allocation and Leadership Opportunity
1:28:57
Neuroregenerative Research for Veterans
1:29:29
Political Transition and Advocacy Challenges
1:30:00
Philanthropic Partnerships and State Commitment
1:30:32
Ambush Meeting with New Attorney General
1:31:03
Personal Loss and Future Advocacy
1:32:06
Reed Foundation Support for Opioid Treatment
1:33:10
Strategic Outreach to Preserve Initiative
1:34:13
Governor Perry’s Support and Texas Opportunity
1:34:45
Historical Legislative Process for Psychedelic Law
1:35:15
Legislative Passage and Voting Details
1:35:46
Public Education on Psychedelic Benefits
1:36:18
Texas as a National Leader in Psychedelic Therapy
1:37:21
Comparative Legislative Timelines and Opportunities
1:38:23
Partnerships with VA and University Systems
1:38:54
Funding Allocation and Drug Development Solicitation
1:39:25
Clinical Trial Design and Safety Protocols
1:39:55
Intellectual Property and State ROI Considerations
1:40:27
Long-Term Treatment Infrastructure and Support Services
1:41:29
FDA Approval Process and Clinical Trial Funding
1:42:01
Texas Medical Expertise and Institutional Capacity
1:42:32
Global Impact of Texas Leadership in Psychedelic Therapy
1:43:36
Texas and Other States Joining the Initiative
1:44:07
Key Political Figures Supporting the Effort
1:44:38
Senator Donald Douglas and Kentucky’s Role
1:45:09
Governor Perry’s Commitment to Veterans
1:45:40
Political Support Across Party Lines
1:46:11
Personal Story of Military Family Influence
1:47:14
Governor Perry’s Experience with Veterans in War
1:48:19
Private Sector Support for Veteran Care
1:48:50
Veteran Community as a Priority Group
1:49:21
Psychedelic Therapy for PTSD and TBI
1:50:26
Safety and Dosage Considerations in Psychedelic Use
1:51:27
Psychedelics as a Tool for Criminal Justice Reform
1:52:01
Spiritual and Societal Benefits of Psychedelic Treatment
1:53:37
Discussion of Spiritual Affliction and Human Divinity
1:54:09
Personal Commitment to Psychedelic Therapy
1:55:45
Logistics of Celexa Discontinuation
1:56:17
Travel and Preparation for Abigan Session
1:56:49
Abigan and 5-MeO-DMT Experience Overview
1:57:54
Spiritual Significance of Psychedelic Medicine
1:58:24
Public Engagement Strategies in Texas
1:59:26
National Policy and Legislative Support
2:00:26
Education of Media and Public Awareness
2:01:31
Implementation of Treatment Centers and Training
2:02:03
Technical Considerations for Abigan Delivery
2:03:35
Parables in Faith Traditions
2:04:00
Contemporary American Society as a Parable
2:04:06
Dynamic Multicultural Society and Dehumanization
2:04:24
Government Systems as Revenue Units
2:04:39
Commodification of Human Problems
2:05:00
Risk of Social Collapse
2:05:12
Shift in Social Consciousness
2:05:45
Hope and Prayer for the Nation
2h 58m⏭ 2
2h 21m⏭ 3
2h 53m⏭ 2
3h 1m⏭ 2
2h 54m⏭ 2
3h 35m
3h 7m⏭ 2
2h 39m⏭ 2
2h 58m⏭ 2
2h 34m⏭ 3
2h 19m
2h 49m⏭ 2
48m⏭ 1
1h 22m
1h 16m⏭ 4
1h 50m⏭ 3
1h 0m⏭ 1
31m⏭ 1
4h 6m⏭ 2
2h 15m⏭ 2
1h 1m
1h 28m⏭ 2
1h 42m⏭ 3
1h 0m⏭ 2